Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France. Read the Press Release
Biophytis Trading will resume on February 14th, 2020 at 09:00 CET. Read the Press Release
Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure. Read the Press Release
Biophytis shares trading is suspended pending a new press release. Read the Press Release
Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS. Read the Press Release
Biophytis SARA-INT Phase 2b study, evaluating the efficacy of Sarconeos (BIO101) in sarcopenia, has now achieved over 50% patient recruitment. Read the Press Release
Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release
Biophytis has appointed Evelyne Nguyen as CFO and Strengthens Senior Management Team. Read the Press Release
Biophytis Receives FDA Approval to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with Duchenne Muscular Dystrophy (DMD). Read the Press Release
Biophytis to attend Biotech Showcase™ 2020 in San Francisco, USA. Read the Press Release